News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Flamel Technologies (FLML) Announces Completion Of A Commercial Supply Agreement With GlaxoSmithKline (GSK) For Drug In Phase III Trials


10/19/2005 5:12:30 PM

LYON, France--(BUSINESS WIRE)--Dec. 21, 2004--Flamel Technologies S.A. ("Flamel") (Nasdaq:FLML) announced today that Flamel and Glaxo-Smith Kline ("GSK") have signed an agreement whereby Flamel will supply GSK with commercial supplies of Flamel's Micropump(R) formulation of a major, currently-marketed, GSK drug. The provisions of the agreement include payments such that Flamel will not have cash outlays in connection with equipment to be used.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES